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Background: Cactus (Opuntia ﬁcus-indica) ﬁber was shown to promote weight loss in a 3-month clinical
investigation. As demonstrated by in vitro studies, cactus ﬁber binds to dietary fat and its use results inKey Words:
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reduced absorption, which in turn leads to reduced energy absorption and ultimately the reduction of
body weight.
Objective: The objective of our study was to elucidate the dietary fat binding capacity of cactus ﬁber
through determination of fecal fat excretion in healthy volunteers.
Subjects and Methods: This clinical investigation was performed as a double-blind, randomized, placebo-
controlled, crossover study in healthy subjects for a period of approximately 45 days. Twenty healthy
volunteer subjects were randomized to receive cactus ﬁber or placebo, 2 tablets thrice daily with main
meals. All subjects were provided with meals during the study period (except washout) according to a
standardized meal plan, with 35% of daily energy need coming from fat. Two 24-hour feces samples were
collected during both the baseline and treatment periods for analysis of the fat content.
Results: Cactus ﬁber showed an increased fecal fat excretion compared with placebo (mean [SD] ¼
15.79% [5.79%] vs 4.56% [3.09%]; P o 0.001). No adverse events were reported throughout the study
period.
Conclusions: Cactus ﬁber has been shown to signiﬁcantly promote fecal fat excretion in healthy adults.
The results of our study support the hypothesis that cactus ﬁber helps in reducing body weight by
binding to dietary fat and increasing its excretion, thus reducing dietary fat available for absorption.
ClinicalTrials.gov identiﬁer: NCT01590667.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The prevalence of overweight and obesity has been recognized
as a global epidemic, affecting not only developed but also devel-
oping countries.1 World Health Organization estimates showed that
in 2008, more than 1.4 billion adults worldwide were overweight
and that 4500 million were obese.2 Notably, 68.8% of adults aged
20 years and older were overweight or obese in the United States
during 2009 to 2010.3 Data from Eurostat4 suggest that the
predominance of obesity is as alarming in Europe—more than 50%
of the European Union population is overweight or obese.
Accumulating evidence indicates a strong association between
obesity and elevated health risks, including insulin resistance,Inc. This is an open access article u
pharm Europe Ltd, Invision
, United Kingdom.
ah).hypertriglyceridemia, decrease in HDL level, and increase in LDL
level, leading to life-threatening diseases such as type 2 diabetes
mellitus, hypertension, cardiovascular disease, stroke, and certain
cancers.1,5–7 It is also of no surprise that obesity tends to
negatively affect quality of life.1,6,8
The increasing proportion of dietary fat is believed to be 1 of
the major contributors to the prevalence of obesity worldwide.
Studies have suggested that energy derived from fat plays a more
signiﬁcant role in promoting obesity than energy derived from
carbohydrates and proteins.9–11 It is therefore reasonable to
hypothesize that weight loss can be achieved by reducing the
consumption of fat, or the absorption of dietary fat.
The drastic increase of obesity worldwide has spurred research
into more effective weight management solutions. Modern ther-
apeutic strategies usually focus on the manipulation of enzymes
and biomolecules involved in fat metabolism. Lipase inhibitors,
agents that act on the inhibition of enzymes responsible for thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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safer choice of treatment for weight management.12,13 However,
these antiobesity agents are not without downsides. Apparent
gastrointestinal side effects, such as increased defecation, soft
stools, fatty oils evacuation, and oily spotting have been
reported.13 Also, the question of possible liver damage associated
with the use of lipase inhibitors remains unanswered.14
Due to concerns over drug toxicity and side effects, there is
increasing interest to seek alternative nonpharmacologic
approaches from natural sources for weight management. Opuntia
ﬁcus-indica (also known as nopal) is a species of cactus found
abundantly in Mexico and over a large area of Latin America, South
Africa, and the Mediterranean.15 The fruit (prickly pear or cactus
pear) and the pad (cladode) of the cactus are common ingredients
in Mexican cuisine. Besides culinary use, prickly pear fruit has
been traditionally used in the management of ulcer, dyspnea,
glaucoma, liver conditions, wounds, and fatigue.16 The Opuntia
genus is also widely used by Pima Indians for treatment of
diabetes and hyperlipidemia. Previous ﬁndings suggested that
daily consumption of prickly pear fruit could be beneﬁcial to
cardiovascular health through a reduction of total cholesterol
and LDL-C,17 whereas the intake of cactus pad could potentially
lower fasting blood glucose levels.18 Aqueous extracts from prickly
pear have been shown to exhibit high total antioxidant capacity.
The sources of the antioxidant properties were mainly vitamin C,
with small fractions of carotenoids and vitamin E.15
On the other hand, the cladode of Opuntia ﬁcus-indica is a rich
source of dietary ﬁber,19 and its dehydrated powder has been
shown to bind to dietary fat in laboratory settings. It is postulated
that dietary fat bound by the ﬁber complex is not available for
digestion and is eventually eliminated unabsorbed, thus helping to
reduce energy intake and promote weight loss.20 A cactus ﬁber
preparation (IQP-G-002AS), supplied by InQpharm Group (Hert-
fordshire, United Kingdom) used in our study is derived from the
dehydrated cladode of Opuntia ﬁcus-indica and fortiﬁed with soluble
ﬁber from Acacia spp. The cactus ﬁber preparation is composed of
soluble and insoluble dietary ﬁbers, including cellulose and hemi-
cellulose, and is standardized in its fat binding capacity (1 g
compound binds to 10 g fat). The in vivo efﬁcacy of the standardized
cactus ﬁber on weight loss was previously established during a
14-week study on 123 obese or overweight subjects. The double-
blind, randomized, placebo-controlled, parallel group study showed
that subjects who consumed cactus ﬁber experienced signiﬁcant
weight loss compared with the placebo group.21
Postulation of weight loss due to fat binding and reduction in fat
absorption would lack credibility unless such an effect could be
demonstrated under the controlled conditions of a human clinical
trial.22 The quantiﬁcation of fat excreted in fecal matter should be
used as the primary assessment to examine the reduction of dietary
fat absorption and establish that a product has fat-binding proper-
ties.22,23 A pilot study (unpublished) had previously been conducted
to evaluate the efﬁcacy of cactus ﬁber on fecal fat excretion, in
comparison to placebo. Cactus ﬁber was shown to signiﬁcantly
increase fecal fat excretion. However, several design limitations of
the pilot trial hindered drawing a ﬁrm conclusion. Our study aimed
to elucidate the dietary fat binding capacity of cactus ﬁber through
determination of fecal fat excretion in healthy white subjects.Patients and Methods
Our double-blind, randomized, placebo-controlled, crossover
single-center study was conducted from May to July 2012 in Berlin,
Germany, and was approved by the ethics committee of the Charite ́
Universitätsmedizin before initiation. This clinical investigation was
performed according to the principles of the World MedicalAssociation (Declaration of Helsinki), as well as the European Union
recommendations for Good Clinical Practice (CPMP/ICH/135/95), the
International Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human Use ICH E6
(R1)24 and ICH E3.25 Subjects were randomized using random-
ization scheme of BiAS version 9.2 (2009) (Goethe-Universität
Frankfurt/M., epsilon-Verlag Hochheim Darmstadt, Germany) in
blocks of 4. Both the investigator and the subjects were kept blind
to the allocation. The study was registered on ClinicalTrials.gov
(identiﬁer: NCT01590667). All subjects provided written informed
consent before any study-related procedures were carried out.
Subjects
Subjects who met the inclusion criteria were aged between 18
and 60 years, had body mass index between 20 and 30, reported
regular bowel movements (self-reported 1-2 bowel movements
per day), and used appropriate birth control methods (for female
subjects).
The exclusion criteria were known hypersensitivity to the
ingredients of the investigational product, history of or concurrent
endocrine disorders, use of other weight management products,
use of antidepressants, uncontrolled hypertension, history of or
concurrent gastrointestinal diseases, bariatric surgery, history of
eating disorder, use of medications/products that could affect
gastrointestinal function, pregnant or nursing, or excursions of
safety parameters.
Study intervention
The study period was approximately 45 days, as described in
Figure 1. Subjects fulﬁlling all inclusion criteria entered a 7-day
baseline period (Baseline 1 [B1]), during which they were provided
with a standardized diet containing 35% of fat in total energy
required. Daily energy needs were estimated for each subject
depending on sex, age, and physical activity.26 Subjects were given
a diary at B1 and were instructed to record their daily food intake
and to adhere strictly to the meal plan based on the food provided.
Inspection of food diary was carried out at every subsequent clinic
visit to ensure compliance. All subjects were instructed to take
placebo tablets during B1. Subjects compliant with the meal plan
and investigational product (IP) regimen during B1 entered a 7-
day intervention phase (Intervention 1) and were randomized to
either receive cactus ﬁber tablets or matching placebo, 2 tablets
TID after each main meal. Each cactus ﬁber tablet contains 500 mg
standardized cactus ﬁber, as well as common tableting excipients.
Identical placebo tablets were manufactured based on the same
formulation, but the active ingredient was replaced by a mixture of
microcrystalline cellulose (316.5 mg) and calcium hydrogen phos-
phate dihydrate (183.5 mg).
A 7-day washout period followed by a second baseline meas-
urement period (Baseline 2) took place before subjects were
crossed over to the second treatment arm (Intervention 2). Sub-
jects continued to consume the standardized diet provided
throughout the study, except during the washout period.
All subjects needed to collect 2 24-hour stool samples during
each baseline and intervention week. All bowel movements within
a 24-hour period (beginning from 12:00 AM to 11:59 PM of each
day) were collected on Day 5 and Day 6, or on Day 6 and Day 7.
Samples were collected in tightly closed containers (Fecontainer,
AT Medical BV, the Netherlands), labeled with the subject number
and collection date, and refrigerated (at r41C) until stool collec-
tion was completed and transferred to a freezer (r–201C). The
stool samples were collected and delivered under controlled
condition in a cooler box with thermal packs to the laboratory
for analysis.
Screening Baseline 1 Intervention 1 Baseline 2 Intervention 2 Final visitWash-out
V1
7 days 0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7 7 days 3 days0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7
V2 V3* V4 V5 V6
Placebo IP I IP IIPlacebo
Blood
sampling
Blood
sampling
Stool collection (On Day 5 and 6, or Day 6 and 7)
Randomization*
Figure 1. Clinical trial study schedule comparing and analyzing the fecal fat extraction effect of cactus ﬁber. There were 6 clinical visits (V1–V6) throughout the study period.
V1 ¼ screening þ blood sampling; V2 ¼ Baseline 1 (subjects were given a standardized meal, with placebo); V3 ¼ subjects compliant to the meal plan and investigational
product regimen were randomized to receive cactus ﬁber or placebo and a 7-day washout period followed; V4 ¼ baseline 2 (similar to Baseline 1); V5 ¼ subjects compliant
to the meal plan and investigational product regimen were crossed over to the second treatment arm; V6 ¼ blood sampling. Stool was collected on both Day 5 and Day 6, or
Day 6 and Day 7 of baseline and intervention period. IP ¼ investigational product.
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The end point of note was difference in the amount of fat
excreted in the feces (relative to fat intake) with administration of
cactus ﬁber compared with the placebo.
Efﬁcacy parameter
The stool samples from each container of 24-hour collection
were homogenized and the fat content in the feces was quantiﬁed
by the near-infrared reﬂectance analysis27 at 700 to 2500 nm,
using FENIR 8820-Infrared Analyzer (Stimotron, Wendelstein,
Germany). The mean values from the 2 24-hour samples were
used as the measurement results. Absolute fat mass excreted in the
feces was then determined from the stool weight.
Safety parameters
Venous blood samples were obtained at screening and the ﬁnal
visit of the study. Full blood count and clinical chemistry, including
liver function parameters (ie, alanine transaminase, aspartate
aminotransferase, γ-glutamyltransferase, alkaline phosphatase,
and bilirubin), renal function parameters (ie, creatinine, urea),
protein metabolism parameter (ie, uric acid), and lipid metabolism
parameters (ie, total cholesterol, HDL-C, LDL-C, and triglycerides)
were analyzed in a central laboratory. Adverse events were
recorded at every visit.
Sample size determination
The sample size was determined based on the results of a
previous pilot trial conducted on standardized cactus ﬁber (unpub-
lished). The effect size was estimated at between 1.16 and 1.27. At a
signiﬁcance level of 5%, power of 80%, and drop out rate estimated at
10%, a sample size of 20 was recommended by the study statistician.
Statistical analyses
Statistical analysis was performed with SPSS Statistics software,
version 19 (IBM-SPSS Inc, Armonk, NY).
All efﬁcacy and safety end points received an explorative
examination and were descriptively assessed. The variables were
described by number, mean (SD), and median (number, mean [SD],and median). For ordinal data, (discrete data) the frequency
distribution was performed.
The testing of the primary efﬁcacy end point data was performed
with the nonparametric Mann-Whitney U test by analyzing the rank
sums and supplemented by covariance analysis. The a priori
hypothesis that no residual effects occur within this crossover study
design was tested, as was the occurrence of a period effect.
All secondary outcomes and the concurrent variables were also
evaluated primarily using nonparametric procedures. Due to the
small samples size, Fisher exact test was used. Changes in clinical
parameters over time (repeated measurements) were analyzed
using analysis of variance with respect to differences in groups and
systematic changes over time within each group, respectively.Results
Demographics
Twenty-one subjects were screened, of whom 20 were included
in B1 and randomized (Figure 2). All 20 subjects were included in
the intent-to-treat population. There were 7 men (35.0%) out of the
20 subjects in the trial. The gender distribution was not signiﬁcantly
different between the cactus ﬁber group and the placebo group
(P ¼ 1.000). The baseline characteristics, including age, body
weight, body mass index, and energy requirements of the cactus
ﬁber group and placebo group were similar (Table I).
Energy intake and compliance
Based on the calculated energy requirements, subjects were
categorized into 3 groups that received a standardized meal plan
providing 3 different energy levels: 2200 kcal/d (85 g fat), 2600
kcal/d (101 g fat), or 3000 kcal/d (115 g fat) (Table II). There was no
statistically signiﬁcant difference in energy requirement between
the cactus ﬁber group and the placebo group at the beginning of
the study.
All subjects complied with the IP administration instructions.
Daily stool weight
Mean (SD) daily stool mass across the entire study period was
153.0 (73.7) g, with a range of 34.9 g to 481.4 g. There was no
signiﬁcant difference in the stool mass collected between the cactus
Enrollment
Assessed for eligibility (n = 21)
Baseline 1 (n = 20)
Randomized (n = 20)
Allocated to cactus fibre group (n = 10)
Allocated to cactus fibre group (n = 10)
Allocated Placebo group (n = 10)
Baseline 2 (n = 20)
Lost to follow-up (n = 0) Lost to follow-up (n = 0)
Allocated Placebo group (n = 10)
Reccived allocated intervention (n = 10)
Allocation
Follow-Up
Analysis
Analysed (n = 20) Analysed (n = 20)
Excluded (n = 1)
Violation of exclusion criteria (n = 1)
Reccived allocated intervention (n = 10)
Reccived allocated intervention (n = 10)
Reccived allocated intervention (n = 10)
Figure 2. Subject ﬂow diagram. Twenty-one subjects were screened and 20 subjects were randomized. All 20 subjects were included in the analysis.
Table II
Sample meal plan (2200 kcal/d).
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intervention (P Z 0.05 for all stool collections). Stool mass for both
groups during the intervention periods are detailed in Table III.
Fecal fat excretion
During both intervention periods, the absolute fat mass excreted
was signiﬁcantly more pronounced in the cactus ﬁber group compared
with the placebo group. Based on subjects’ assigned dietary plans and
energy levels, the percentage of fat excreted relative to daily fat intake
(equivalent to 100%) was calculated. At the end of both intervention
periods, there was a signiﬁcant difference in the percentage of dietary
fat excreted between the 2 groups (Table III and Figure 3).
Safety and tolerability
There were no adverse events reported throughout the study
period. There were also no clinically signiﬁcant abnormalities in
the laboratory parameters reported.Table I
Subject characteristics at baseline.
Parameter
Cactus ﬁber (n ¼ 10) Placebo (n ¼ 10)
PMean (SD)
Age (y) 39.8 (10.0) 46.9 (10.9) 0.147
Body weight (kg) 74.8 (7.7) 73.8 (10.2) 0.927
Body mass index 24.9 (2.3) 25.3 (3.0) 0.579
Energy requirements (kcal/d) 2320.2 (344.5) 2340.9 (388.3) 0.971Discussion
Fat excretion and weight loss
A previous study on standardized cactus ﬁber clearly demon-
strated its effect in promoting weight loss in obese or overweight
patients.21 Nevertheless the proposed fat-binding property as a
mechanism of action of cactus ﬁber remains to be clearly established.
The results of our study show that consumption of cactus ﬁber
over a short period (5–6 days) increases the amount of fat excreted
in the feces, with a mean (SD) of 15.11 (6.35) g fat excreted daily in
comparison to 4.33 (2.91) g in the placebo group. In relation to the
amount of daily fat intake, cactus ﬁber facilitates excretion of
15.79% (5.79%) of the dietary fat in comparison to 4.56% (3.09%) inMeal Food Approximate weight (g) Fat content (g)
Breakfast 2 slices bread 100 1
1 Tblsp butter 10 8
2 slices ham 60 3
1 slice cheese 20 9
milk 400 6
Lunch 2 slices toasted bread 250 2
2 Tblsp butter 20 16
2 slices cheese 40 12
1 c cream cheese 125 4
Dinner Prepackaged ready meal 480 24.5
Table III
Stool mass, absolute fat excretion, and percentage of dietary fat excreted (in relation to total fat intake) at both intervention periods.
Parameter
Cactus ﬁber (n ¼ 20) Placebo (n ¼ 20)
PMean (SD) Median Range Mean (SD) Median Range
Stool mass (g) 162.3 (59.5) 155.9 42.8–300.1 133.5 (64.3) 138.6 44.9–284.7 0.148
Absolute fat excretion (g) 15.11 (6.35) 14.06 4.31–28.77 4.33 (2.91) 3.77 1.28–11.92 o0.001
Dietary fat excreted (%) 15.79 (5.79) 15.06 5.07–28.39 4.56 (3.09) 3.76 1.51–14.02 o0.001
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strengthen the mode of action of cactus ﬁber in binding and
reducing fat absorption. In comparison, a retrospective analysis of
the dose–response relationship of orlistat suggests that mean fecal
fat excretion plateaus at approximately 35% of daily fat intake at
daily doses of Z400 mg/d.28,29 At the recommended dose of
orlistat 120 mg TID and 60 mg TID, the inhibition of dietary fat
absorption is estimated to be at 30% and 25%, respectively.29
Flaxseed, another food ingredient with high dietary ﬁber content,
which has previously been suggested to be able to reduce fat
digestion, was found to result in higher fecal fat excretion of 4.96
(0.31) g per day, compared with 3.20 (0.33) g per day in control
when given as drink at a dosage of 3 g ﬁber per day for 7 days.30
Even though there are differences in the study design, our study
showed that cactus ﬁber may possess higher fat excretion capacity
in comparison to ﬂaxseed-extracted ﬁber; the difference may be
due to differences in the compositions of ﬂaxseed ﬁber and cactus
ﬁber in the studies. Although the ﬂaxseed-extracted ﬁber com-
prises arabinoxylants, galactose, fructose residues, and some
pectin,30 the cladode of Opuntia ﬁcus-indica is reported to contain
40% to 50% dry weight of dietary ﬁbers, which consist of mucilage,
gum, pectin, and hemicellulose.31–33 Bendsen et al34 showed that
an increase in calcium intake can lead to fecal fat loss, with a mean
(SD) excretion of 11.5 (1.4) g fecal fat per day from a high calcium
diet (2300 mg/d) as opposed to 5.4 (0.5) g per day fecal fat from
a low calcium diet (700 mg/d). It should be noted that the levels
of calcium included in the diets of this study are much higher than
the levels used in the active and placebo tablets of our study
(81 mg and 337 mg calcium per day, respectively) and the fecal fat
excretion observed is unlikely a result of calcium found in the IPs.
Approximate weight loss effect from the absolute amount of fat
excreted from cactus ﬁber consumption can be extrapolated from a
model proposed by Hall et al,35 which takes into account the
compensatory effects of the body toward energy expenditure
during weight loss. Given that 1 g fat equals 9 kcal energy, 15.11
g fat excreted per day would correspond to 136 kcal of reduced
energy intake per day. Assuming—according to the model of Hall
et al35—that a permanent 10 kcal energy deﬁcit would result in a
weight loss of 0.45 kg, and that 1 year is needed to achieve 50%,18
15.79 p<0.001*
4.56
16
14
12
10
%
8
6
4
2
0
Cactus fibre Placebo
Figure 3. Percentage of dietary fat excreted (in relation to total fat intake). Error
bar represents 1 standard error of mean. With cactus ﬁber, mean (SD) 15.79%
(5.79%) of fat was excreted, in comparison with placebo, which contributed 4.56%
(3.09%) of fat excretion (P o 0.001). *Signiﬁcant difference.and 3 years to achieve 95% of this weight loss, the 136 kcal energy
deﬁcit per day would lead to a loss of approximately 3 kg body
mass after 1 year, and 5.8 kg after 3 years. As quoted above, the
reported fecal fat excretion of orlistat at 180 mg/d is 25%, yet in a
study of 16 weeks’ duration, orlistat at 60 mg TID has been shown
to only result in a 3.50 kg weight loss compared with 1.90 kg in the
placebo group, with a net weight loss of 1.6 kg.36 In comparison,
2.4 kg mean net body weight loss was observed over a 3-month
period during a previous study of cactus ﬁber,21 suggesting a more
pronounced weight loss effect size than explained by the reduced
energy intake due to fat excretion alone. The additional weight
loss effect may be attributed to other functional properties of
ﬁbers contained in cactus ﬁber; for example, the effects of ﬁbers
on promoting satiety37,38 and delaying absorption of nutrients
during digestion,32,33,39 which have been frequently reported in
literature. Despite being a nonpharmacologic ingredient, cactus
ﬁber demonstrated substantial efﬁcacy in weight management.21
Study design and limitations
Our study design incorporated considerably long baseline
periods of 7 days, to adhere subjects to the standardized diet plan
and also to ensure compliance of subjects to the study protocol, in
both stool collection and investigational product intake. There is
variation in terms of daily stool weight, ranging from 34.9 g to
481.4 g, with a mean (SD) of 153.0 (73.7) g. This ﬁgure is never-
theless in line with the ﬁndings of Cummings et al,40 who reported
stool weight with a range of 72 to 470 g/d in the different
populations of the world. Our investigation decided against a
longer study period with additional stool collection, considering
that the task of stool collection may be unpleasant or stressful for
subjects and that the use of standardized diet in a longer study
may reduce compliance with the diet plan and stool collection.
Additionally, a second baseline measurement was incorporated
after the washout period to further rule out any possible carryover
effect. These measures were perceived to be beneﬁcial in ensuring
the consistency and reliability of results.
A limitation of our study is that it does not provide indication if
the increase in fecal fat excretion can be sustained and if tolerance/
adaptation effects may develop as a result of longer-term con-
sumption of cactus ﬁber. Nonetheless, a sustained positive effect of
cactus ﬁber on weight management has been clearly established in
a previous clinical investigation.21
A subgroup analysis carried out among subjects assigned to a
diet of different daily energy requirement levels showed a possible
positive relationship between the amount of fat intake and
percentage of fat excreted (data not shown). However, due to the
small sample size at each energy level, the correlation needs
further conﬁrmation in a study with a larger population.
Safety
Cactus ﬁber demonstrated a good tolerability proﬁle as a
product derived from natural sources. No adverse events were
reported throughout the study.
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In our study, the administration of cactus ﬁber resulted in
signiﬁcant increases of dietary fat excretion in the feces. This
ﬁnding conﬁrmed the in vivo fat-binding capability of cactus ﬁber;
furthermore, it supports the hypothesis that its weight loss effect
is achieved by reducing dietary fat absorption, which leads to
lower energy intake and promotes weight loss. Because cactus
ﬁber promotes dietary fat excretion, and previous research has
indicated that cactus ﬁber exerts a noticeable hypolipidemic
effect,17 future investigations on the effects on cactus ﬁber on
blood lipid levels may add value to the research of its use beyond
weight management.Acknowledgments
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